Key Points
-
Amazon’s commerce divisions don’t generate a substantial amount of profits.
-
Amazon’s revenue growth appears slow.
-
AWS and advertising services are a key part of the Amazon investment thesis.
- 10 stocks we like better than Amazon ›
Amazon’s commerce divisions don’t generate a substantial amount of profits.
Amazon’s revenue growth appears slow.
AWS and advertising services are a key part of the Amazon investment thesis.
Amazon (NASDAQ: AMZN) is well known for its e-commerce platform, where you can purchase nearly anything. Combined with its wide selection of products, it also offers lightning-fast delivery that consumers have come to demand from every other store.
However, within Amazon’s business are two divisions that are delivering growth much faster than Amazon’s commerce division. Furthermore, they have much higher margins, allowing Amazon’s profits to increase at a much faster rate than revenue. This is Amazon stock’s secret weapon, and it could supercharge returns for investors over the next few years.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Image source: Getty Images.
Amazon’s commerce platform isn’t the top reason to invest in the stock
The vast majority of Amazon’s revenue comes from its commerce business. In the first quarter, online stores and third-party seller services generated $57.4 billion and $36.5 billion in revenue, respectively. Considering Amazon generated $143.3 billion in total sales during Q1, these two combined make up the majority of Amazon’s revenue.
But there are two problems with that.
First, these two business segments are Amazon’s slowest-growing, with online stores experiencing a 5% year-over-year growth rate and third-party seller services increasing by 6%. Because these two make up such a large chunk of Amazon’s total revenue, the slow growth of these two segments drags down Amazon’s overall growth rate, which was 9% for the quarter.
Second, commerce businesses have notoriously slim margins. Because it doesn’t break out the operating margins of individual segments (except for Amazon Web Services, which we’ll address in a moment), it’s impossible to know exactly how much money a segment is making (or losing). If you examine other retailers, such as Walmart or Target, their operating margins typically hover around 5%. If these two segments have similar operating margins to those retail giants, then these divisions don’t contribute significantly to Amazon’s profits. If another segment within Amazon’s business can rapidly grow profits at a much higher margin, then Amazon’s profits will grow substantially from that smaller contribution.
That’s exactly what we’re seeing from AWS and advertising, and this is Amazon’s secret weapon.
AWS and advertising play a huge role in Amazon’s profit margins
In Q1, AWS, Amazon’s cloud computing division, produced a stellar 17% growth rate and generated $29.3 billion in revenue — not far off from third-party seller services. However, it delivered a 39% operating margin. This allowed AWS to account for 63% of Amazon’s total operating profits during Q1 despite making up only 19% of revenue.
So, even though Amazon’s commerce business is the most forward-facing of the company, it doesn’t deliver the lion’s share of profits.
Advertising is likely the same way, although it’s buried within the commerce division. Advertising has been Amazon’s fastest-growing business over the past few years. The consumer data it has is unparalleled, as it includes first-party data that allows advertisers to understand customer purchasing habits. This enabled Amazon’s ad revenue to soar, consistently making it Amazon’s fastest-growing segment over the past few years. Q1 was no exception, with revenue rising 18% year over year.
As the biotech industry surges forward in a wave of innovation, Regeneron (NASDAQ:REGN) stands out as a stalwart titan. Renowned for its flagship drugs Eylea and Dupixent, Regeneron has carved a path to success in treating eye diseases and eczema. The soaring popularity of these treatments has propelled Regeneron's stock to unprecedented heights, displaying a trajectory of steady growth since 2020.
Despite facing recent challenges due to inventory issues with its leading products, Regeneron's resilience shines through. These setbacks, although causing temporary profit stumbles, underscore the immense demand for Regeneron's medications. Investors with foresight recognize that resolving these issues will likely catapult Regeneron back to robust sales figures.
Eylea, in particular, has emerged as a favored choice among patients, securing its position ahead of competitors. Regeneron's strategic pivot towards entering burgeoning fields like gene therapy promises a treasure trove of cutting-edge products on the horizon. Thus, any temporary dips in Regeneron's stock price present savvy investors with ripe opportunities to capitalize on future growth prospects.
The Ascendancy of Sarepta Therapeutics (SRPT)In the realm of rare diseases, Sarepta Therapeutics (NASDAQ:SRPT) reigns supreme, crafting a niche portfolio focusing on Duchenne Muscular Dystrophy (DMD). The jewel in Sarepta's crown, Elevidys, has captivated investors with its promise as a gene therapy treatment. Following its FDA approval in June, Elevidys has sparked fervor in the biotech world.
While the initial approval was a part of an accelerated process, hinting at a promising launch, Sarepta has diligently navigated the regulatory landscape to secure full FDA acceptance. This pivotal milestone now allows Sarepta Therapeutics to broaden Elevidys's approved indications, extending hope to a wider array of patients in need.
Buoyed by its recent Q1 2024 financial report, showcasing an earnings per share (EPS) beat and a remarkable 55% revenue surge year-over-year, Sarepta stands poised for greater accolades.
Imagery Sources: madamF / Shutterstock.com (Regeneron), Freedom Studio / Shutterstock.com (Sarepta Therapeutics)
Gene-Editing Giants: A Deep Dive into CRISPR Therapeutics (CRSP)Unfortunately, Amazon doesn’t break out the advertising segment’s operating margin, but if we use another advertising-focused company as an example, Meta Platforms, we can see that an operating margin of 40% or greater are feasible. This makes advertising another key profit contributor, and investors need to keep an eye on it to ensure it continues to deliver market-beating growth.
Because both divisions have outgrown their commercial counterparts in recent years, Amazon’s operating margin has improved significantly. As long as these two entities maintain their current performance, this trend is likely to continue.
AMZN Operating Margin (TTM) data by YCharts
Although Amazon’s top-line growth may appear slow, it is offset by rapidly rising profit growth. This is driven by two high-margin business segments: AWS and advertising. As long as these two continue to grow at a rapid pace, Amazon’s profits will rise in tandem. There are numerous tailwinds propelling these two divisions higher, which gives me confidence that Amazon can deliver long-term outperformance for its shareholders.
Should you invest $1,000 in Amazon right now?
Before you buy stock in Amazon, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $674,432!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,005,854!*
Now, it’s worth noting Stock Advisor’s total average return is 1,049% — a market-crushing outperformance compared to 180% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of July 7, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool’s board of directors. Keithen Drury has positions in Amazon and Meta Platforms. The Motley Fool has positions in and recommends Amazon, Meta Platforms, Target, and Walmart. The Motley Fool has a disclosure policy.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.




